Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
RATIONALE: Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.
PURPOSE: This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix).
Genetic: microarray analysis
Procedure: conventional surgery
Procedure: neoadjuvant therapy
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus|
- Histologic response [ Designated as safety issue: No ]
- Steroid receptor status as assessed by immunohistochemistry (IHC) [ Designated as safety issue: No ]
- Growth and apoptosis as assessed by IHC [ Designated as safety issue: No ]
|Study Start Date:||October 2003|
|Primary Completion Date:||September 2010 (Final data collection date for primary outcome measure)|
- Compare the efficacy of medroxyprogesterone, in terms of induction of histologic response, in patients with progesterone receptor-positive vs progesterone receptor-negative endometrioid adenocarcinoma of the uterine corpus.
- Determine the early and late changes in gene expression at 72 hours and 21 days in patients treated with this drug.
- Examine the mechanisms surrounding the dynamic changes in endometrial tumor cells by determining possible correlations among histologic response, steroid receptor status, immunohistochemical measures of growth and apoptosis, and gene expression profiles in patients treated with this drug.
OUTLINE: This is a pilot, multicenter study.
Patients receive medroxyprogesterone intramuscularly once approximately 3 weeks before surgical hysterectomy.
A subset of 15 patients has tissue collected by pipelle biopsy or curettage at baseline, 72 hours after medroxyprogesterone therapy, and during surgery for gene expression arrays.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
|United States, Connecticut|
|Helen and Harry Gray Cancer Center at Hartford Hospital|
|Hartford, Connecticut, United States, 06102-5037|
|George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus|
|New Britain, Connecticut, United States, 06050|
|United States, Illinois|
|University of Illinois Cancer Center|
|Chicago, Illinois, United States, 60612-7243|
|United States, Iowa|
|Holden Comprehensive Cancer Center at University of Iowa|
|Iowa City, Iowa, United States, 52242-1002|
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|United States, Nevada|
|Women's Cancer Center - Lake Mead|
|Las Vegas, Nevada, United States, 89102|
|United States, Ohio|
|Charles M. Barrett Cancer Center at University Hospital|
|Cincinnati, Ohio, United States, 45267|
|Case Comprehensive Cancer Center|
|Cleveland, Ohio, United States, 44106-5065|
|United States, Oregon|
|Williamette Gynecologic Oncology PC|
|Portland, Oregon, United States, 97213|
|United States, South Carolina|
|Hollings Cancer Center at Medical University of South Carolina|
|Charleston, South Carolina, United States, 29425|
|Study Chair:||Richard Zaino, MD||Milton S. Hershey Medical Center|
|Investigator:||Harrison G. Ball, MD||Levine Cancer Center at UMass Medical Center - Memorial Campus|